Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations After Multiple Doses

Amgen · Phase 1 · Not yet recruiting · Enrollment 356

NCT07921316

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Maridebart Cafraglutide: SC Presentation 1n/rn/rn/rn/r
Maridebart Cafraglutide: SC Presentation 2n/rn/rn/rn/r

Not shown

  • Maridebart Cafraglutide: SC Presentation 1: endpoint not reported
  • Maridebart Cafraglutide: SC Presentation 2: endpoint not reported